Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Research & Development: 2012-2024

Historic Research & Development for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $93.3 million.

  • Coherus Oncology's Research & Development rose 23.58% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.2 million, marking a year-over-year increase of 2.81%. This contributed to the annual value of $93.3 million for FY2024, which is 14.71% down from last year.
  • Latest data reveals that Coherus Oncology reported Research & Development of $93.3 million as of FY2024, which was down 14.71% from $109.4 million recorded in FY2023.
  • Over the past 5 years, Coherus Oncology's Research & Development peaked at $363.1 million during FY2021, and registered a low of $93.3 million during FY2024.
  • Its 3-year average for Research & Development is $134.0 million, with a median of $109.4 million in 2023.
  • Per our database at Business Quant, Coherus Oncology's Research & Development soared by 154.35% in 2021 and then plummeted by 45.11% in 2023.
  • Over the past 5 years, Coherus Oncology's Research & Development (Yearly) stood at $142.8 million in 2020, then skyrocketed by 154.35% to $363.1 million in 2021, then tumbled by 45.10% to $199.4 million in 2022, then slumped by 45.11% to $109.4 million in 2023, then fell by 14.71% to $93.3 million in 2024.